CN113891747A - 诱导免疫细胞活性的组合物及使用该组合物治疗疾病的方法 - Google Patents
诱导免疫细胞活性的组合物及使用该组合物治疗疾病的方法 Download PDFInfo
- Publication number
- CN113891747A CN113891747A CN202080036171.3A CN202080036171A CN113891747A CN 113891747 A CN113891747 A CN 113891747A CN 202080036171 A CN202080036171 A CN 202080036171A CN 113891747 A CN113891747 A CN 113891747A
- Authority
- CN
- China
- Prior art keywords
- composition
- cancer
- tumor
- subject
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 222
- 210000002865 immune cell Anatomy 0.000 title claims abstract description 162
- 238000000034 method Methods 0.000 title claims abstract description 116
- 230000000694 effects Effects 0.000 title claims abstract description 49
- 230000001939 inductive effect Effects 0.000 title claims abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 13
- 201000010099 disease Diseases 0.000 title description 8
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 266
- 239000000556 agonist Substances 0.000 claims abstract description 136
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims abstract description 90
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims abstract description 90
- 239000013592 cell lysate Substances 0.000 claims abstract description 69
- 244000309459 oncolytic virus Species 0.000 claims description 165
- 206010028980 Neoplasm Diseases 0.000 claims description 149
- 210000004027 cell Anatomy 0.000 claims description 117
- 239000012190 activator Substances 0.000 claims description 90
- 229950010550 resiquimod Drugs 0.000 claims description 63
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 claims description 63
- 210000001519 tissue Anatomy 0.000 claims description 46
- 238000002347 injection Methods 0.000 claims description 39
- 239000007924 injection Substances 0.000 claims description 39
- 238000000265 homogenisation Methods 0.000 claims description 37
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 claims description 36
- 238000010254 subcutaneous injection Methods 0.000 claims description 34
- 239000007929 subcutaneous injection Substances 0.000 claims description 34
- 241000700605 Viruses Species 0.000 claims description 32
- 239000006166 lysate Substances 0.000 claims description 31
- 230000035755 proliferation Effects 0.000 claims description 25
- 206010009944 Colon cancer Diseases 0.000 claims description 24
- 241000700584 Simplexvirus Species 0.000 claims description 24
- 210000004698 lymphocyte Anatomy 0.000 claims description 24
- 108020001507 fusion proteins Proteins 0.000 claims description 23
- 102000037865 fusion proteins Human genes 0.000 claims description 23
- 108010042215 OX40 Ligand Proteins 0.000 claims description 21
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 20
- 102000017578 LAG3 Human genes 0.000 claims description 20
- 229960002751 imiquimod Drugs 0.000 claims description 20
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims description 20
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 19
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 claims description 19
- 102100027207 CD27 antigen Human genes 0.000 claims description 19
- 102100038078 CD276 antigen Human genes 0.000 claims description 19
- 101150013553 CD40 gene Proteins 0.000 claims description 19
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 19
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 19
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 claims description 19
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 19
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 19
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 19
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 19
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 19
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 19
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims description 19
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims description 19
- 101001055145 Homo sapiens Interleukin-2 receptor subunit beta Proteins 0.000 claims description 19
- 101000863882 Homo sapiens Sialic acid-binding Ig-like lectin 7 Proteins 0.000 claims description 19
- 101000863883 Homo sapiens Sialic acid-binding Ig-like lectin 9 Proteins 0.000 claims description 19
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 19
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 19
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 19
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims description 19
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 19
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims description 19
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 claims description 19
- 102000002698 KIR Receptors Human genes 0.000 claims description 19
- 108010043610 KIR Receptors Proteins 0.000 claims description 19
- 108010082739 NADPH Oxidase 2 Proteins 0.000 claims description 19
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 19
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 claims description 19
- 102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 claims description 19
- 102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 claims description 19
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 19
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 19
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 19
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 19
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 19
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 19
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 19
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 19
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 18
- 231100000135 cytotoxicity Toxicity 0.000 claims description 18
- 230000003013 cytotoxicity Effects 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 18
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 16
- 206010027476 Metastases Diseases 0.000 claims description 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 16
- 208000029742 colonic neoplasm Diseases 0.000 claims description 16
- 230000009401 metastasis Effects 0.000 claims description 16
- 230000032459 dedifferentiation Effects 0.000 claims description 15
- 230000004069 differentiation Effects 0.000 claims description 15
- 201000005202 lung cancer Diseases 0.000 claims description 15
- 208000020816 lung neoplasm Diseases 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 230000005764 inhibitory process Effects 0.000 claims description 14
- 230000002601 intratumoral effect Effects 0.000 claims description 14
- 230000003902 lesion Effects 0.000 claims description 14
- 108010002350 Interleukin-2 Proteins 0.000 claims description 13
- 102000000588 Interleukin-2 Human genes 0.000 claims description 13
- 101100215487 Sus scrofa ADRA2A gene Proteins 0.000 claims description 13
- 238000011065 in-situ storage Methods 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 13
- 206010025323 Lymphomas Diseases 0.000 claims description 12
- 239000005557 antagonist Substances 0.000 claims description 12
- 238000011066 ex-situ storage Methods 0.000 claims description 12
- 239000000834 fixative Substances 0.000 claims description 12
- 210000000822 natural killer cell Anatomy 0.000 claims description 12
- 206010006187 Breast cancer Diseases 0.000 claims description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims description 11
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 11
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 11
- 206010033128 Ovarian cancer Diseases 0.000 claims description 11
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 11
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 11
- 206010060862 Prostate cancer Diseases 0.000 claims description 11
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 11
- 206010038389 Renal cancer Diseases 0.000 claims description 11
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 11
- 201000001441 melanoma Diseases 0.000 claims description 11
- 201000002528 pancreatic cancer Diseases 0.000 claims description 11
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 10
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 10
- 108090001005 Interleukin-6 Proteins 0.000 claims description 10
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 10
- 108091034117 Oligonucleotide Proteins 0.000 claims description 10
- 201000010982 kidney cancer Diseases 0.000 claims description 10
- 238000000527 sonication Methods 0.000 claims description 10
- 208000035462 Biphenotypic Acute Leukemia Diseases 0.000 claims description 9
- 206010005003 Bladder cancer Diseases 0.000 claims description 9
- 206010005949 Bone cancer Diseases 0.000 claims description 9
- 208000018084 Bone neoplasm Diseases 0.000 claims description 9
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 9
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 9
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 9
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 9
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 9
- 208000032612 Glial tumor Diseases 0.000 claims description 9
- 206010018338 Glioma Diseases 0.000 claims description 9
- 102000013462 Interleukin-12 Human genes 0.000 claims description 9
- 108010065805 Interleukin-12 Proteins 0.000 claims description 9
- 108090000172 Interleukin-15 Proteins 0.000 claims description 9
- 102000003812 Interleukin-15 Human genes 0.000 claims description 9
- 102000003810 Interleukin-18 Human genes 0.000 claims description 9
- 108090000171 Interleukin-18 Proteins 0.000 claims description 9
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 9
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims description 9
- 208000000172 Medulloblastoma Diseases 0.000 claims description 9
- 206010027406 Mesothelioma Diseases 0.000 claims description 9
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 9
- 208000034578 Multiple myelomas Diseases 0.000 claims description 9
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 9
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 9
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 9
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 9
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 9
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 9
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 9
- 206010057644 Testis cancer Diseases 0.000 claims description 9
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 9
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 9
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 9
- 206010047741 Vulval cancer Diseases 0.000 claims description 9
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 9
- 201000010881 cervical cancer Diseases 0.000 claims description 9
- 201000004101 esophageal cancer Diseases 0.000 claims description 9
- 201000010175 gallbladder cancer Diseases 0.000 claims description 9
- 206010017758 gastric cancer Diseases 0.000 claims description 9
- 201000010536 head and neck cancer Diseases 0.000 claims description 9
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 9
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 9
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 9
- 201000007270 liver cancer Diseases 0.000 claims description 9
- 208000014018 liver neoplasm Diseases 0.000 claims description 9
- 230000033001 locomotion Effects 0.000 claims description 9
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 9
- 201000000349 mediastinal cancer Diseases 0.000 claims description 9
- 208000025113 myeloid leukemia Diseases 0.000 claims description 9
- 208000018280 neoplasm of mediastinum Diseases 0.000 claims description 9
- 206010038038 rectal cancer Diseases 0.000 claims description 9
- 201000001275 rectum cancer Diseases 0.000 claims description 9
- 201000000849 skin cancer Diseases 0.000 claims description 9
- 201000011549 stomach cancer Diseases 0.000 claims description 9
- 201000003120 testicular cancer Diseases 0.000 claims description 9
- 201000002510 thyroid cancer Diseases 0.000 claims description 9
- 206010044285 tracheal cancer Diseases 0.000 claims description 9
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 9
- 201000005102 vulva cancer Diseases 0.000 claims description 9
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 8
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 6
- 206010061309 Neoplasm progression Diseases 0.000 claims description 6
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 6
- 238000010255 intramuscular injection Methods 0.000 claims description 6
- 239000007927 intramuscular injection Substances 0.000 claims description 6
- 239000007928 intraperitoneal injection Substances 0.000 claims description 6
- 238000010253 intravenous injection Methods 0.000 claims description 6
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 6
- 229920002866 paraformaldehyde Polymers 0.000 claims description 6
- 210000000115 thoracic cavity Anatomy 0.000 claims description 6
- 230000005751 tumor progression Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 102000004889 Interleukin-6 Human genes 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 3
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims 1
- 102000004473 OX40 Ligand Human genes 0.000 claims 1
- 230000005965 immune activity Effects 0.000 claims 1
- 230000008102 immune modulation Effects 0.000 claims 1
- 102000002689 Toll-like receptor Human genes 0.000 description 90
- 108020000411 Toll-like receptor Proteins 0.000 description 90
- 241000699666 Mus <mouse, genus> Species 0.000 description 44
- 241000699670 Mus sp. Species 0.000 description 42
- 238000002604 ultrasonography Methods 0.000 description 42
- 239000003446 ligand Substances 0.000 description 34
- 102000004127 Cytokines Human genes 0.000 description 28
- 108090000695 Cytokines Proteins 0.000 description 28
- 102000039446 nucleic acids Human genes 0.000 description 26
- 108020004707 nucleic acids Proteins 0.000 description 26
- 150000007523 nucleic acids Chemical class 0.000 description 26
- 239000002609 medium Substances 0.000 description 24
- 101100481579 Mus musculus Tlr11 gene Proteins 0.000 description 20
- 101100481580 Mus musculus Tlr12 gene Proteins 0.000 description 20
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 20
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 19
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 18
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 16
- 230000028327 secretion Effects 0.000 description 16
- 241001112091 Pseudoviridae Species 0.000 description 14
- 239000012091 fetal bovine serum Substances 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 14
- 230000032258 transport Effects 0.000 description 14
- 241001529453 unidentified herpesvirus Species 0.000 description 13
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 12
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 12
- 230000000259 anti-tumor effect Effects 0.000 description 12
- 230000002147 killing effect Effects 0.000 description 12
- 230000004614 tumor growth Effects 0.000 description 12
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 11
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 11
- 102000008070 Interferon-gamma Human genes 0.000 description 11
- 108010074328 Interferon-gamma Proteins 0.000 description 11
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 11
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 11
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 11
- 229960003130 interferon gamma Drugs 0.000 description 11
- 241000711404 Avian avulavirus 1 Species 0.000 description 10
- 241000709687 Coxsackievirus Species 0.000 description 10
- 241000991587 Enterovirus C Species 0.000 description 10
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 10
- 101000763537 Homo sapiens Toll-like receptor 10 Proteins 0.000 description 10
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 10
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 10
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 10
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 10
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 description 10
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 10
- 102000006992 Interferon-alpha Human genes 0.000 description 10
- 108010047761 Interferon-alpha Proteins 0.000 description 10
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 10
- 241000712079 Measles morbillivirus Species 0.000 description 10
- 102100027010 Toll-like receptor 1 Human genes 0.000 description 10
- 102100027009 Toll-like receptor 10 Human genes 0.000 description 10
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 10
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 10
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 10
- 102100039357 Toll-like receptor 5 Human genes 0.000 description 10
- 102100039387 Toll-like receptor 6 Human genes 0.000 description 10
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 10
- 210000002540 macrophage Anatomy 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 241000701161 unidentified adenovirus Species 0.000 description 10
- 241001430294 unidentified retrovirus Species 0.000 description 10
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 9
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 9
- 238000009169 immunotherapy Methods 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 238000007920 subcutaneous administration Methods 0.000 description 9
- 102000000844 Cell Surface Receptors Human genes 0.000 description 8
- 108010001857 Cell Surface Receptors Proteins 0.000 description 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 8
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 8
- 210000001124 body fluid Anatomy 0.000 description 8
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000001900 immune effect Effects 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 238000003780 insertion Methods 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 230000002062 proliferating effect Effects 0.000 description 8
- 238000011725 BALB/c mouse Methods 0.000 description 7
- 241000702620 H-1 parvovirus Species 0.000 description 7
- 102100030703 Interleukin-22 Human genes 0.000 description 7
- 241000702263 Reovirus sp. Species 0.000 description 7
- 241000711975 Vesicular stomatitis virus Species 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 238000005215 recombination Methods 0.000 description 7
- 210000003501 vero cell Anatomy 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102000026633 IL6 Human genes 0.000 description 6
- 241000700625 Poxviridae Species 0.000 description 6
- 241000125945 Protoparvovirus Species 0.000 description 6
- 230000003213 activating effect Effects 0.000 description 6
- 210000001099 axilla Anatomy 0.000 description 6
- 230000004899 motility Effects 0.000 description 6
- 230000006798 recombination Effects 0.000 description 6
- 101150096316 5 gene Proteins 0.000 description 5
- 241000700618 Vaccinia virus Species 0.000 description 5
- 230000002238 attenuated effect Effects 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000000174 oncolytic effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 241000701242 Adenoviridae Species 0.000 description 4
- 241000712892 Arenaviridae Species 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 4
- 241001533362 Astroviridae Species 0.000 description 4
- 208000003950 B-cell lymphoma Diseases 0.000 description 4
- 241000701412 Baculoviridae Species 0.000 description 4
- 241000714198 Caliciviridae Species 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 241000520666 Carmotetraviridae Species 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 4
- 108091006020 Fc-tagged proteins Proteins 0.000 description 4
- 241000711950 Filoviridae Species 0.000 description 4
- 241000700586 Herpesviridae Species 0.000 description 4
- 102000003816 Interleukin-13 Human genes 0.000 description 4
- 108090000176 Interleukin-13 Proteins 0.000 description 4
- 102000013691 Interleukin-17 Human genes 0.000 description 4
- 108050003558 Interleukin-17 Proteins 0.000 description 4
- 241000723741 Nodaviridae Species 0.000 description 4
- 241000712464 Orthomyxoviridae Species 0.000 description 4
- 241000701945 Parvoviridae Species 0.000 description 4
- 241000150350 Peribunyaviridae Species 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 4
- 241000712907 Retroviridae Species 0.000 description 4
- 241000710924 Togaviridae Species 0.000 description 4
- 108700010877 adenoviridae proteins Proteins 0.000 description 4
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 210000003756 cervix mucus Anatomy 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000002357 endometrial effect Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 108010074108 interleukin-21 Proteins 0.000 description 4
- 210000000581 natural killer T-cell Anatomy 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- 210000003802 sputum Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000000605 viral structure Anatomy 0.000 description 4
- KGRVJHAUYBGFFP-UHFFFAOYSA-N 2,2'-Methylenebis(4-methyl-6-tert-butylphenol) Chemical compound CC(C)(C)C1=CC(C)=CC(CC=2C(=C(C=C(C)C=2)C(C)(C)C)O)=C1O KGRVJHAUYBGFFP-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 108010002616 Interleukin-5 Proteins 0.000 description 3
- 102000000743 Interleukin-5 Human genes 0.000 description 3
- 241000714210 Leviviridae Species 0.000 description 3
- 241000702244 Orthoreovirus Species 0.000 description 3
- 241000709664 Picornaviridae Species 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 108010021843 fluorescent protein 583 Proteins 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000006054 immunological memory Effects 0.000 description 3
- 108010074109 interleukin-22 Proteins 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 241001533460 Barnaviridae Species 0.000 description 2
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 2
- 108020004638 Circular DNA Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000003996 Interferon-beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 101800003050 Interleukin-16 Proteins 0.000 description 2
- 102000049772 Interleukin-16 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000701553 Myoviridae Species 0.000 description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 2
- 241000702247 Reoviridae Species 0.000 description 2
- 238000011053 TCID50 method Methods 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000012510 hollow fiber Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229960001388 interferon-beta Drugs 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 239000000277 virosome Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000702463 Geminiviridae Species 0.000 description 1
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241000701377 Iridoviridae Species 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000701253 Phycodnaviridae Species 0.000 description 1
- 241000701369 Plasmaviridae Species 0.000 description 1
- 241000702072 Podoviridae Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 235000012511 Vaccinium Nutrition 0.000 description 1
- 241000736767 Vaccinium Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000011398 antitumor immunotherapy Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000009028 cell transition Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000001373 regressive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
一种在有需要的受试者中诱导免疫细胞活性的组合物，其包含与所述受试者自体同源的肿瘤细胞裂解物、OX40激动剂和TLR激动剂。使用所述组合物用于治疗受试者病症的方法。
Description
PCT国内申请，说明书已公开。
Claims (35)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019087096 | 2019-05-15 | ||
| CNPCT/CN2019/087096 | 2019-05-15 | ||
| PCT/CN2020/090631 WO2020228828A1 (zh) | 2019-05-15 | 2020-05-15 | 诱导免疫细胞活性的组合物及使用该组合物治疗疾病的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113891747A true CN113891747A (zh) | 2022-01-04 |
Family
ID=73289312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080036171.3A Pending CN113891747A (zh) | 2019-05-15 | 2020-05-15 | 诱导免疫细胞活性的组合物及使用该组合物治疗疾病的方法 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN113891747A (zh) |
| WO (1) | WO2020228828A1 (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107001478A (zh) * | 2014-10-14 | 2017-08-01 | 诺华股份有限公司 | 针对pd‑l1的抗体分子及其用途 |
| CN108135934A (zh) * | 2015-10-19 | 2018-06-08 | 永恒生物科技股份有限公司 | 通过组合疗法治疗实体或淋巴肿瘤的方法 |
| WO2018127713A1 (en) * | 2017-01-09 | 2018-07-12 | Replimune Limited | Altered virus |
| CN108289858A (zh) * | 2015-06-30 | 2018-07-17 | 宾夕法尼亚州立大学托管会 | 用于治疗肿瘤性皮肤疾病的瑞喹莫特局部可注射组合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014022138A2 (en) * | 2012-07-30 | 2014-02-06 | Alex Wah Hin Yeung | Live and in-vivo tumor specific cancer vaccine system developed by co-administration of either at least two or all three of the following components such as tumor cells, an oncolytic virus vector with transgenic expression of gm-csf and an immune checkpoint modulator |
| TW201716084A (zh) * | 2015-08-06 | 2017-05-16 | 葛蘭素史克智慧財產發展有限公司 | 組合物及其用途與治療 |
| JP7410472B2 (ja) * | 2015-09-25 | 2024-01-10 | リリース セラピューティクス エスアー | 免疫調節物質を産生する免疫隔離細胞とのワクチン接種 |
-
2020
- 2020-05-15 CN CN202080036171.3A patent/CN113891747A/zh active Pending
- 2020-05-15 WO PCT/CN2020/090631 patent/WO2020228828A1/zh active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107001478A (zh) * | 2014-10-14 | 2017-08-01 | 诺华股份有限公司 | 针对pd‑l1的抗体分子及其用途 |
| CN108289858A (zh) * | 2015-06-30 | 2018-07-17 | 宾夕法尼亚州立大学托管会 | 用于治疗肿瘤性皮肤疾病的瑞喹莫特局部可注射组合物 |
| CN108135934A (zh) * | 2015-10-19 | 2018-06-08 | 永恒生物科技股份有限公司 | 通过组合疗法治疗实体或淋巴肿瘤的方法 |
| WO2018127713A1 (en) * | 2017-01-09 | 2018-07-12 | Replimune Limited | Altered virus |
Non-Patent Citations (3)
| Title |
|---|
| IDIT SAGIV-BARFI 等: "Eradication of spontaneous malignancy by local immunotherapy", SCIENCE TRANSLATIONAL MEDICINE, vol. 10, 31 January 2018 (2018-01-31), pages 3 * |
| KASIEWICZ, M.J. 等: "Toll-like receptor ligands in conjunction with agonist anti-OX40 mAb immunotherapy possess differential capacity to revive anergic self-reactive CD8 T cells", THE JOURNAL OF IMMUNOLOGY, vol. 196, no. 1 * |
| VOO, K.S. 等: "Selective targeting of Toll‐like receptors and OX40 inhibit regulatory T–cell function in follicular lymphoma", INTERNATIONAL JOURNAL OF CANCER, vol. 135, pages 2834 - 2846, XP055739918, DOI: 10.1002/ijc.28937 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020228828A1 (zh) | 2020-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7455399B2 (ja) | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 | |
| JP7159304B2 (ja) | 腫瘍および／または癌の処置のための医薬のための単離された組換え体腫瘍溶解性アデノウイルス、医薬組成物、およびそれらの使用 | |
| JP6954648B2 (ja) | 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法 | |
| Donnelly et al. | Measles virus causes immunogenic cell death in human melanoma | |
| JP2022002531A (ja) | 改変された腫瘍溶解性ウイルス | |
| CN109554353B (zh) | 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 | |
| KR20150038066A (ko) | 종양 세포, 암세포파괴 바이러스 벡터 및 면역 체크포인트 조절인자를 갖는 암 백신 시스템 | |
| KR20170003920A (ko) | 종양분해성 백시니아 바이러스 | |
| KR20150041181A (ko) | 종양 용해 백시니아 바이러스 암 치료법 | |
| US20210252135A1 (en) | Treatment using oncolytic virus | |
| JP7239911B2 (ja) | 腫瘍溶解性ワクシニアウイルスおよびｎｋ細胞を含む治療剤、ならびに腫瘍および／またはがんの治療のための薬物のためのその使用 | |
| JP7132339B2 (ja) | 腫瘍を治療するための仮性狂犬病ウイルス | |
| WO2019080537A1 (zh) | 包含溶瘤病毒和car-nk细胞的治疗剂及应用、药盒、治疗肿瘤和/或癌症的方法 | |
| CN116173193A (zh) | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 | |
| Wetzel et al. | MCP‐3 (CCL7) delivered by parvovirus MVMp reduces tumorigenicity of mouse melanoma cells through activation of T lymphocytes and NK cells | |
| JP2021526842A (ja) | Ｉ型インターフェロン及びｃｄ４０−配位子を用いる腫瘍溶解性ウイルス又は抗原提示細胞媒介性癌治療 | |
| CN110996980A (zh) | 一种用于治疗肿瘤的病毒 | |
| Kurena et al. | Generation and functional in vitro analysis of semliki forest virus vectors encoding TNF-α and IFN-γ | |
| WO2023088437A1 (zh) | 重组武装溶瘤病毒组合物及其在til过继治疗中的用途 | |
| CN113891747A (zh) | 诱导免疫细胞活性的组合物及使用该组合物治疗疾病的方法 | |
| JP2021522190A (ja) | 腫瘍を治療するためのコクサッキーウイルスｂ群 | |
| JP2020537534A (ja) | 腫瘍を治療するためのエコーウイルス | |
| WO2020230785A1 (ja) | 細胞融合を誘導するワクシニアウイルス及びその利用 | |
| KR20230038776A (ko) | 중간엽 줄기세포에 의한 케모카인 및 사이토카인의 표적 수송을 위한 면역 요법 | |
| Wongthida | Understanding, and exploiting, the contribution of the immune system to the therapeutic efficacy of oncolytic virotherapy with vesicular stomatitis virus (VSV) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |